SCHEMBL2016580

SCHEMBL2016580

O=C(c1cccc2ccccc12)c1c[nH]c2ncnc(Nc3cccc(OCc4ccccc4)c3)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 10/20 0.49
SIRT2 Q8IXJ6 2/20 0.49
JAK2 O60674 1/20 0.49
JAK3 P52333 1/20 0.49
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
PTK6 Q13882 1/20 0.46
HDAC6 Q9UBN7 2/20 0.43
EGFR P00533 1/20 0.43
TTBK1 Q5TCY1 1/20 0.43
TTBK2 Q6IQ55 1/20 0.43
AURKB Q96GD4 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023296 0.84 BRAF (0.46) BTKMEN1MAPTKMT2AL3MBTL1
SCHEMBL2021226 0.83 ERBB2 (0.52) BTKERBB2
SCHEMBL2020565 0.83 NR1H4 (0.56) BTKSIRT2JAK2JAK3HDAC6
SCHEMBL2022444 0.82 BTK (0.51) BTKEGFRHIF1A
SCHEMBL2022472 0.82 EGFR (0.48) BTKJAK3EGFRLMNAMAPK1
SCHEMBL2021419 0.82 EGFR (0.54) EGFRAURKB
SCHEMBL2020584 0.81 ABCG2 (0.55) BTKJAK3EGFRKDM4EMEN1
SCHEMBL2021310 0.80 BRAF (0.45) BTK
SCHEMBL2023282 0.80 GCGR (0.47) BTKTTBK1TTBK2NPC1ALDH1A1
SCHEMBL2020574 0.79 BTK (0.48) BTKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds DPYD, TYMP, DHFR BTK 1600/4885SIRT2 1969/4885JAK2 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.